Claims for Patent: 8,329,419

Summary for Patent: 8,329,419

Title:	GLP-1 receptor agonist bioassays
Abstract:	Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLP-I receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.
Inventor(s):	Nicolaou; Michalis (San Diego, CA), Bancroft; Frederick Charles (Carlsbad, CA), Herich; John Patrick (Cardiff, CA), Gupta; Swati (San Diego, CA), Lwin; Aung Naing (Carlsbad, CA)
Assignee:	Amylin Pharmaceuticals, LLC (San Diego, CA) Astrazeneca Pharmaceuticals LP (Wilmington, DE)
Application Number:	12/990,693
Patent Claims:	1. A method for detecting or measuring GLP-1 receptor agonist activity of a test compound comprising: (i) preparing a sample which comprises a test compound and 6-23 (clone 6) cells; (ii) detecting and quantitatively measuring cAMP in the sample using a cell-based assay; and (iii) correlating the amount of cAMP in the sample to the GLP-1 receptor agonist activity of the test compound. 2. The method of claim 1, wherein the sample comprises (i) a pharmaceutical composition which comprises the test compound and (ii) 6-23 (clone 6) cells. 3. The method of claim 1, wherein the cell-based assay is an enzyme-linked immunosorbent assay. 4. The method of claim 1, wherein the cell-based assay is a homogeneous time-resolved fluorescence assay. 5. The method of claim 1, wherein the test compound is exenatide; liraglutide; albiglutide; taspoglutide; lixisenatide; [N.sup.e-(17-carboxyheptadecanoic acid)Lys.sup.20]exendin-4-NH.sub.2; [N.sup.e-(17-carboxy-heptadecanoyl)Lys.sup.32]exendin-4-NH.sub.2; [desamino-His.sup.1,N.sup.e-(17-carboxy-heptadecanoyl)-Lys.sup.20]exendin- -4-NH.sub.2; [Arg.sup.12,27,NLe.sup.14,N.sup.e-(17-carboxyhepta-decanoyl)Lys.sup.32]ex- endin-4-NH.sub.2; [N.sup.e-(19-carboxynonadecanoylamino)Lys.sup.20]-exendin-4-NH.sub.2; [N.sup.e-(15-carboxypentadecanoylamino)Lys.sup.20]exendin-4-NH.sub.2; [N.sup.e-(13-carboxytridecanoylamino)Lys.sup.20]exendin-4-NH.sub.2; [N.sup.e-(11-carboxy-undecanoylamino)Lys.sup.20]-exendin-4-NH.sub.2; exendin-4-Lys.sup.40(.epsilon.-MPA)-NH.sub.2; exendin-4-Lys.sup.40(.epsilon.-AEEA-AEEA-MPA)-NH.sub.2; exendin-4-Lys.sup.40(.epsilon.-AEEA-MPA)-NH.sub.2; exendin-4-Lys.sup.40(.epsilon.-MPA)-albumin; exendin-4-Lys.sup.40(.epsilon.-AEEA-AEEA-MPA)-albumin; exendin-4-Lys.sup.40(.epsilon. AEEA-MPA)-albumin; GLP-1(7-38); desamino-His.sup.7,Arg.sup.26,Lys.sup.34(N.sup.e-(.gamma.-Glu(N-.alpha.-h- exadecanoyl)))-GLP-1(7-37); desamino-His.sup.7, Arg.sup.26,Lys.sup.34, (N.sup..epsilon.octanoyl)-GLP-1(7-37); Arg.sup.26,34,Lys.sup.38(N.sup..epsilon.-(.omega.-carboxypentadecanoyl))-- GLP-1(7-38); Arg.sup.26,34,Lys.sup.36(N.sup..epsilon.-(.gamma.-Glu(N-.alpha.hexadecano- yl)))-GLP-1(7-36); or any peptide comprising the amino acid sequence of any one of SEQ ID NOs:1-40 and 43-45; wherein the peptide comprising the amino acid sequence of any one of SEQ ID NOs:25-40 may optionally be linked to the amino acid sequence of SEQ ID NO:42; and wherein the test compound is optionally amidated. 6. A method for detecting or measuring GLP-1 receptor agonist activity of a test compound comprising: (a) preparing a sample which comprises a test compound and 6-23 (clone 6) cells; (b) forming a reaction mixture by combining: (i)the sample from step (a); (ii) a compound comprising an anti-cAMP antibody; and (iii) a compound comprising a detectably labeled cAMP; (c) quantitatively measuring cAMP in the sample; and (d) correlating the amount of cAMP in the sample to the GLP-1 receptor agonist activity of the test compound. 7. The method of claim 6, wherein the sample comprises (i) a pharmaceutical composition which comprises the test compound and (ii) 6-23 (clone 6) cells. 8. The method of claim 6, further comprising incubating the reaction mixture. 9. The method of claim 6, wherein the anti-cAMP antibody is linked to a rare earth cryptate or a rare earth chelate. 10. The method of claim 6, wherein the anti-cAMP antibody is linked to a terbium cryptate, a europium cryptate, a dysprosium cryptate, a samarium cryptate, a neodymium cryptate, a terbium chelate, a europium chelate, a dysprosium chelate, a samarium chelate, a neodymium chelate, or a combination of two or more thereof. 11. The method of claim 6, wherein the anti-cAMP antibody is an anti-cAMP monoclonal antibody. 12. The method of claim 6, wherein the detectably-labeled cAMP is a cAMP linked to a fluorescent moiety. 13. The method of claim 6, wherein the fluorescent moiety is allophycocyanin, allophycocyanin B, phycocyanin C, phycocyanin R, or a combination of two or more thereof. 14. The method of claim 6, wherein the fluorescent moiety is a crosslinked allophycocyanin. 15. The method of claim 6, wherein the sample comprises (i) a pharmaceutical composition which comprises exenatide; (ii) 6-23 (clone 6) cells; and (iii) cAMP linked to a fluorescent moiety selected from the group consisting of allophycocyanin, allophycocyanin B, phycocyanin C, phycocyanin R, or a combination of two or more thereof. 16. The method of claim 6, wherein the test compound is exenatide; liraglutide; albiglutide; taspoglutide; lixisenatide; [N.sup..epsilon.-(17-carboxyheptadecanoic acid)Lys.sup.20]exendin-4-NH.sub.2; [N.sup..epsilon.-(17-carboxy-heptadecanoyl)Lys.sup.32]exendin-4-NH.sub.2; [desamino-His.sup.1,N.sup..epsilon.-(17-carboxy-heptadecanoyl)-Lys.sup.20- ]exendin-4-NH.sub.2; [Arg.sup.12,27,NLe.sup.14,N.sup..epsilon.-(17-carboxyhepta-decanoyl)Lys.s- up.32]exendin-4-NH.sub.2; [N.sup..epsilon.-(19-carboxynonadecanoylamino)Lys.sup.20]-exendin-4-NH.su- b.2; [N.sup..epsilon.-(15-carboxypenta-decanoylamino)Lys.sup.20]exendin-4-- NH.sub.2; [N.sup..epsilon.-(13-carboxytridecanoylamino)Lys.sup.20]exendin-- 4-NH.sub.2; [N.sup..epsilon.-(11-carboxy-undecanoylamino)Lys.sup.20]-exendin-4-NH.sub- .2; exendin-4-Lys.sup.40(.epsilon.-MPA)-NH.sub.2; exendin-4-Lys.sup.40(.epsilon.-AEEA-AEEA-MPA)-NH.sub.2; exendin-4-Lys.sup.40(.epsilon.-AEEA-MPA)-NH.sub.2; exendin-4-Lys.sup.40(.epsilon.-MPA)-albumin; exendin-4-Lys.sup.40(.epsilon.-AEEA-AEEA-MPA)-albumin; exendin-4-Lys.sup.40(.epsilon.-AEEA-MPA)-albumin; GLP-1(7-38); desamino-His.sup.7,Arg.sup.26,Lys.sup.34(N.sup..epsilon.-(.gamma.-Glu(N-.- alpha.-hexadecanoyl)))-GLP-1(7-37); desamino-His.sup.7Arg.sup.26,Lys.sup.34, (N.sup..epsilon.octanoyl)-GLP-1(7-37); Arg.sup.26,34,Lys.sup.38(N.sup..epsilon.-(.omega.-carboxypentadecanoyl))-- GLP-1(7-38); Arg.sup.26,34,Lys.sup.36(N.sup..epsilon.-(.gamma.-Glu(N-.alpha.-hexadecan- oyl)))-GLP-1(7-36); or any peptide comprising the amino acid sequence of any one of SEQ ID NOs:1-40 and 43-45; wherein the peptide comprising the amino acid sequence of any one of SEQ ID NO:25-40 may optionally be linked to the amino acid sequence of SEQ ID NO:42; and wherein the test compound is optionally amidated. 17. A method for detecting or measuring GLP-1 receptor agonist activity of a GLP-1 receptor agonist compound comprising: (a) preparing a sample comprising a GLP-1 receptor agonist compound and 6-23 (clone 6) cells; (b) adding an agent to stimulate the sample from step (a) to produce cAMP in the 6-23 (clone 6) cells; (c) forming a reaction mixture by combining: (i) the sample from step (b); (ii) an anti-cAMP monoclonal antibody linked to Europium-cryptate capable of generating emitted fluorescence at a measuring wavelength of about 620 nm; and (iii) cAMP linked to a fluorescent moiety capable of emitting fluorescence at a correcting wavelength of about 665 nm; wherein the reaction mixture comprises a buffer capable of lysing the 6-23 (clone 6) cells; (d) irradiating the reaction mixture from step (c) at a single excitation wavelength of about 337 nm by an external radiation source; (e) simultaneously measuring both the emitted fluorescence at about 620 nm due to the first compound and the emitted fluorescence at about 665 nm due to the second compound which takes account interference parameters of the reaction mixture; (f) calculating a corrected fluorescence for the fluorescence emitted by the first compound at about 620 nm based on the fluorescence emitted by the second compound at about 665 nm; (g) correlating the corrected fluorescence reading to the presence or quantitative amount of cAMP in the sample; and (h) correlating the amount of cAMP in the sample to the GLP-1 receptor agonist activity of exenatide. 18. The method of claim 17, wherein the sample comprises (i) a pharmaceutical composition which comprises exenatide as the GLP-1 receptor agonist compound, and (ii) 6-23 (clone 6) cells. 19. The method of claim 17, further comprising incubating the reaction mixture. 20. The method of claim 17, wherein the test compound is exenatide; liraglutide; albiglutide; taspoglutide; lixisenatide; [N.sup..epsilon.-(17-carboxyheptadecanoic acid)Lys.sup.20]exendin-4-NH.sub.2; [N.sup..epsilon.-(17-carboxy-heptadecanoyl)Lys.sup.32]exendin-4-NH.sub.2; [desamino-His.sup.1,N.sup..epsilon.-(17-carboxy-heptadecanoyl)-Lys.sup.20- ]exendin-4-NH.sub.2; [Arg.sup.12,27,NLe.sup.14,N.sup..epsilon.-(17-carboxyhepta-decanoyl)Lys.s- up.32]exendin-4-NH.sub.2; [N.sup..epsilon.-(19-carboxynonadecanoylamino)Lys.sup.20]-exendin-4-NH.su- b.2; [N.sup..epsilon.-(15-carboxypenta-decanoylamino)Lys.sup.20]exendin-4-- NH.sub.2; [N.sup..epsilon.-(13-carboxytridecanoylamino)Lys.sup.20]exendin-- 4-NH.sub.2; [N.sup..epsilon.-(11-carboxy-undecanoylamino)Lys.sup.20]-exendin-4-NH.sub- .2; exendin-4-Lys.sup.40(.epsilon.-MPA)-NH.sub.2; exendin-4-Lys.sup.40(.epsilon.-AEEA-AEEA-MPA)-NH.sub.2; exendin-4-Lys.sup.40(.epsilon.-AEEA-MPA)-NH.sub.2; exendin-4-Lys.sup.40(.epsilon.-MPA)-albumin; exendin-4-Lys.sup.40(.epsilon.-AEEA-AEEA-MPA)-albumin; exendin-4-Lys.sup.40(.epsilon.-AEEA-MPA)-albumin; GLP-1(7-38); desamino-His.sup.7,Arg.sup.26,Lys.sup.34(N.sup..epsilon.-(.gamma.-Glu(N-.- alpha.-hexadecanoyl)))-GLP-1(7-37); desamino-His.sup.7,Arg.sup.26,Lys.sup.34, (N.sup..epsilon.octanoyl)-GLP-1(7-37); Arg.sup.36,34,Lys.sup.38(N.sup..epsilon.-(.omega.-carboxypentadecanoyl))-- GLP-1(7-38); Arg.sup.26,34,Lys.sup.36(N.sup..epsilon.-(.gamma.-Glu(N-.alpha.-hexadecan- oyl)))-GLP-1(7-36); or any peptide comprising the amino acid sequence of any one of SEQ ID NOs:1-40 and 43-45; wherein the peptide comprising the amino acid sequence of any one of SE ID NOs:25-40 may optionally be linked to the amino acid sequence of SEQ ID NO:42; and wherein the test compound is optionally amidated.

Details for Patent 8,329,419

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	04/15/2014		2028-05-23
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471	07/27/2016		2028-05-23